ALTRAZEAL Press Releases

09/16/2009

ULURU INC. PRESENTS RESULTS OF FIRST RANDOMIZED CLINICAL TRIAL FOR ALTRAZEAL™ AT THE SYMPOSIUM ON ADVANCED WOUND CARE (SAWC) FALL MEETING IN WASHINGTON D.C.

Addison, Texas, September 16, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either AltrazealTM or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing. Read More

07/29/2009

ULURU INC TO PRESENT ALTRAZEAL™ CLINICAL EVIDENCE AT THE AMERICAN PODIATRIC MEDICAL ASSOCIATION (APMA) ANNUAL SCIENTIFIC MEETING IN TORONTO, CANADA

Addison, Texas, July 29, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that the application of Altrazeal™ and best clinical practice will be demonstrated in a hands-on Wound Care Pre Conference Workshop at the APMA Annual Scientific Meeting July 28 - August 2. In addition, clinical evidence on the treatment of wounds using Altrazeal™ Transforming Powder Dressing will be presented on posters during the meeting. Read More

05/05/2009

ULURU Inc. announces ALTRAZEAL™ Clinical Experience Published in the International Wound Journal

Addison, Texas, May 5, 2009; ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence utilizing Altrazeal™ Nanoflex Transforming Powder Dressing has been published in the respected peer-reviewed publication, International Wound Journal. The article, which is the first peer-review publication detailing clinical experience using Altrazeal™, was authored by a team of clinicians and scientists working at Southern Arizona Limb Salvage Alliance (“SALSA”) at the University of Arizona College of Medicine, located in Tucson, Arizona. Read More

04/23/2009

ULURU to present Clinical Evidence and Advanced Research on ALTRAZEAL at the Society for Advance Wound Care Conference for 2009

Addison, Texas, April 23, 2009; ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence on the treatment of wounds using Altrazeal™ along with pre-clinical and physical data on Altrazeal™ and Altrazeal™ Silver will be presented at the annual Society for Advance Wound Care Conference (“SAWC”) being held in Grapevine, Texas, April 26-30, 2009. The clinical evidence and data will be presented on posters on display during the meeting. Read More

04/01/2009

ALTRAZEAL™ Clinical Evidence to be prepared at the American Professional Wound Care Association (APWCA)

Addison, Texas, April 1, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that clinical evidence on the treatment of wounds using Altrazeal™ Transforming Powder Dressing, and data on the physical properties of Altrazeal™ Silver will be presented at the annual APWCA National Clinical Conference in Philadelphia, April 2-5, 2009. The work will be presented in podium presentations and with posters on display during the meeting. Read More.

03/13/2009

ULURU INC. Announces Appointment of Jeffrey A. Niezgoda

Addison, Texas, March 13, 2009; ULURU Inc. (NYSE Alternext: ULU) today announced the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Chairman of the Company’s Scientific Advisory Board. Currently, Dr. Jeffrey Niezgoda is the Medical Director of The Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. Luke's Medical Center, Aurora Health Care, in Milwaukee, Wisconsin. Read More.

03/13/2009

ULURU INC. to Present at the Diabetic Foot Global Conference

Addison, Texas, March 13, 2009; ULURU Inc. (NYSE Alternext: ULU) announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex™ Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting in Los Angeles, California March 19-21. The work will be presented on posters that will be on display during the meeting. Read More.

11/04/2008

ULURU INC. ANNOUNCES THE LAUNCH OF THE Altrazeal™ WEBSITE

Addison, Texas, November 4, 2008; ULURU Inc. (NYSE Alternext: ULU) today announced that it has launched a new Altrazeal™ website designed to provide information to both health care professionals and patients on the clinical benefits of Altrazeal™.

10/30/2008

ULURU INC. HOSTS SYMPOSIUM ON Altrazeal™ AT THE 23RD ANNUAL CLINICAL SYMPOSIUM ON ADVANCES IN SKIN & WOUND CARE

Las Vegas, NV, October 30, 2008; ULURU Inc. (NYSE Alternext: ULU) – Clinical updates and new case studies on the application of Altrazeal™ - Transforming Powder Dressing were presented yesterday at a special session of this year's annual Clinical Symposium on Advances in Skin & Wound Care. The session was hosted by ULURU Inc.

10/28/2008

ULURU INC. ANNOUNCES POSTER PRESENTATIONS AT THE 23RD ANNUAL “CLINICAL SYMPOSIUM ON ADVANCES IN SKIN & WOUND CARE”

Addison, Texas, October 28, 2008; ULURU Inc. (NYSE Alternext: ULU) today announced that it will present two posters at the “Clinical Symposium on Advances in Skin and Wound Care” being held in Las Vegas from October 27 to October 30, 2008.

10/21/2008

ULURU INC. ANNOUNCES THE COMMENCEMENT OF FIRST CLINICAL STUDY USING ALTRAZEAL™ SILVER - Multi-Center Study in Skin Graft Donor Site Patients

Addison, Texas, October 21, 2008; ULURU Inc. (NYSE Alternext: ULU) today announced that it has commenced a clinical study to evaluate patients with graft donor sites treated with ALTRAZEAL Silver compared with a market leading silver containing carboxymethylcellulose dressing. The study will be conducted at four clinical sites with 40 evaluable patients being enrolled. The first study site has been initiated and the Company plans to initiate additional sites within the next 30-days.

10/13/2008

ULURU Inc. to Host Satellite Symposium at the 23rd Annual 'Clinical Symposium on Advances in Skin & Wound Care'

ADDISON, Texas, Oct. 13, ULURU, Inc. (NYSE Alternext: ULU) today announced that it will be sponsoring a Satellite Symposium titled "ALTRAZEAL - Transforming Clinical Wound Management - from Science to Outcomes With An Innovative Powder Dressing" on October 29, 2008 at 7 a.m. at the "Clinical Symposium On Advances in Skin and Wound Care" being held in Las Vegas.

09/30/2008

ULURU Inc. Announces the Filing of a 510k Submission with the FDA for ALTRAZEAL Silver

ADDISON, Texas, Sept. 30, ULURU, Inc. (Amex: ULU) today announced that it has filed a 510k application with the United States Food and Drug Administration (FDA) for ALTRAZEAL Silver. Preclinical studies conducted to support the filing have shown that superior healing rates in numerous porcine wound models have been achieved relative to competitive silver dressings.

05/19/2008

ULURU INC. Announces the Launch Plan for ALTRAZEAL™

Addison, Texas, May 8, 2008; ULURU Inc. (AMEX. ULU) today announced the Company’s launch plan for ALTRAZEAL and the commercial availability of the product commencing the week of May 19, 2008. ALTRAZEAL is the first wound care dressing to be developed from our nanoparticles™ aggregate technology. It is an easy to apply and remove powder hydrogel that in the presence of body fluids rapidly converts to a gel material which fills and seals the wound, promoting an optimal moist healing environment and reduces the need for multiple dressing changes. Read More

02/20/2008

ULURU INC. Provides Details on ALTRAZEAL™ Launch

Addison, Texas, February 20, 2008; ULURU Inc. (AMEX: ULU) today provided an update on the status of its wound care franchise. In preparation for the launch of ALTRAZEAL our first wound care product, which is scheduled to occur in the second quarter 2008, the Company is conducting numerous market research surveys. Read More.